Sign up to receive Dana-Farber Spotlight, our email newsletter.View the current issueSubscribe nowUnsubscribe from mailings
Ellen BerlinDirector of Media Relations617firstname.lastname@example.org
Molly McHaleAssociate Director of Media Relations617email@example.com
Dr. Paul Richardson commented on the US Food and Drug Administration’s decision to expand the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients with newly diagnosed multiple myeloma.
Dr. Lawrence Shulman wrote about his work in Rwanda and providing access to life-saving advances in cancer treatment through the collaborations of the Rwandan Ministry of Health, Partners in Health, and Dana-Farber.
Dana-Farber physicians including Dr. Barrett Rollins and Dr. Kenneth C. Anderson talked about the next generation of cancer-fighting drugs at the 14th annual Breakfast with the Doctors in Palm Beach.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: